Robotic surgery pioneer Intuitive Surgical, Inc. (NASDAQ:ISRG) reported earnings last week, and -- as is typically the case with earnings reports -- all eyes were on revenue, profit, and whether or not the company beat analysts' estimates. While analyzing these metrics is an important part of determining the success or failure of a given quarter, a review of management commentary in the earnings release and conference call can provide investors with much-needed perspective and provide insight regarding what to expect from the future. In these forums, Intuitive Surgical's management gave its take concerning share repurchases, technological advances, and increased spending estimates for the coming year.
Significant share repurchase
In December 2016, Intuitive Surgical announced that it had increased its stock repurchase plan to $3 billion. In the earnings press release, it revealed that it is exercising the bulk of that authorization:
"Intuitive Surgical has entered into an accelerated share repurchase program (the "ASR Program") on January 24, 2017, with Goldman, Sachs & Co. ("Goldman") pursuant to which Intuitive Surgical will repurchase $2.0 billion of its common stock from Goldman... The Company expects to fund the ASR Program through cash and investments."
The company ended the quarter with $4.8 billion in cash and no debt on its balance sheet, so while it possesses the means to execute on this promise, this is a significant reduction in its war chest. Buybacks can be a great way to allocate capital, as they reduce the amount of outstanding shares, which increases the value of those that remain. All too often, however, repurchases near all-time highs can backfire if share prices fall. How this will play out remains to be seen.
Why the buyback?
On the conference call, CEO Gary Guthart had this to say:
"Overall, we are committed to the thoughtful return of excess capital to shareholders and believe our buyback program will serve shareholders well."
There is more than one way to return excess capital to shareholders. Some would argue that a dividend might be a better option, but that often marks a more permanent obligation than what the company's board and management deem prudent. The share buyback, on the other hand, carries with it no expectations for indefinite continuation, which gives management more flexibility regarding future investments of capital. Personally, I believe that the company's management is in the best position to decide how to allocate capital, so I support the decision.
Intuitive Surgical has a newer version of its surgical robot, the da Vinci SP (the SP for single-port), in trials to be approved for additional procedures and eventually for release. Guthart explained the path forward for the system:
"Sp is a platform technology that allows high dexterity access with great 3D vision to confined surgical spaces. Early surgeon response to Sp in the trials has been very positive. We anticipate initiating an Sp IDE trial in the United States for transoral robotic surgery as well as submitting a 510(k) for urologic applications, both in the first half of 2017."
The system is designed for getting into tight spaces and expanding the areas that surgeons can access with robotics. Transoral surgery involves removal of cancer from difficult to reach areas of the mouth and throat, and urologic applications concern areas such as the urinary tract and male reproductive organs. This marks the next evolution in the surgical robot space -- a necessary step, as competition in the space will eventually materialize.
Potential new technology
In September of 2016, the company revealed a joint venture with Fosun Pharma (its China partner) to produce devices to diagnose and provide low-cost treatment for lung cancer. Guthart provided an update on the developing technology:
"We're also making good progress on our flexible robotics platform. First targeted to address the acute need and diagnosis of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection is important. The technology underpinning the system is based on computer controlled catheters, advanced image processing, and sophisticated sensing. As we mentioned previously, this system is in its early stages of our human clinical experience."
It's a brilliant move: This platform will be separate and distinct from any existing da Vinci platform, opening an entirely new addressable market.
Increased R&D spending
Intuitive believes that the potential market created by the aforementioned technologies is considerable, and it announced it is accelerating the process of getting to market by increasing its R&D budget significantly for 2017:
"Bringing new platforms to the market represents a significant investment, and we expect to invest up to $80 million more in 2017 than our typical operating expense run rate growth."
Considering its annual R&D expenditures for 2015 and 2016 were $197 million and $239 million, respectively, adding an additional $80 million amounts to a budget increase of between 33% and 40%. This marks a significant departure from historical spending patterns and might raise the question...
Why so much?
Regarding the significant increase in spending in 2017, Guthart further explained:
"...the biggest spend on a platform launch is actually the year before launch. That's where both you're building a lot of products, you're doing a lot of validations, you're getting ready, you're doing a lot of the staging. .. the growth rate in '17 is unusual... we'd expect op expense growth rate in '18 as well, but more aligned with historical norms."
This appears to be an indication that the release of the Sp platform will likely occur later in 2017 or 2018. These appear to be reasonable and necessary expenditures when taken in the light of a pending new product release.
Foolish final thoughts
Financial metrics taken in a vacuum may not provide the information necessary to make an informed investment decision. Each of these quotes, when taken in conjunction with the earnings release, provides investors with much-needed clarity and a better understanding of management's mindset and strategic thinking for navigating the future.
Having been an investor in Intuitive Surgical company for many years, the additional clarity afforded by this information confirms my thesis and belief that Intuitive Surgical will remain the leader in the surgical robotics industry, even with the potential for future competition.